Health and Fitness Health and Fitness
Tue, November 24, 2009
Mon, November 23, 2009
Sun, November 22, 2009
Fri, November 20, 2009
Thu, November 19, 2009
Wed, November 18, 2009
Tue, November 17, 2009
Mon, November 16, 2009
Sun, November 15, 2009
Fri, November 13, 2009
Thu, November 12, 2009
Wed, November 11, 2009
Tue, November 10, 2009
Mon, November 9, 2009
Fri, November 6, 2009
Thu, November 5, 2009
Wed, November 4, 2009
Tue, November 3, 2009
Mon, November 2, 2009
Sun, November 1, 2009
Fri, October 30, 2009
Thu, October 29, 2009
Wed, October 28, 2009
Tue, October 27, 2009
Mon, October 26, 2009
Sun, October 25, 2009
Fri, October 23, 2009
Thu, October 22, 2009
Wed, October 21, 2009
Tue, October 20, 2009
Mon, October 19, 2009
Fri, October 16, 2009
Thu, October 15, 2009
Wed, October 14, 2009

Oncolytics Biotech(R) Inc. Announces Results of Second Warrant Expiry Date Acceleration Program


//health-fitness.news-articles.net/content/2009/ .. nd-warrant-expiry-date-acceleration-program.html
Published in Health and Fitness on Tuesday, November 3rd 2009 at 4:30 GMT by Market Wire   Print publication without navigation


CALGARY, Nov. 3 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Corporation") (TSX:ONC; NASDAQ:ONCY) announces, that pursuant to the accelerated expiry of those warrants issued on May 13, 2009, the Corporation has received proceeds of approximately $9.1 million resulting from the exercise of all 3,795,000 warrants. Oncolytics now has 56,662,469 shares issued and outstanding, and cash on hand and available for operations of approximately $23.7 million.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN(R), its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: [ www.oncolyticsbiotech.com ].

This press release contains forward-looking statements. Forward-looking statements, including the Company's expectations as to progress in the clinical trial program and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue Research and Development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as may be required pursuant to applicable securities laws.

%SEDAR: 00013081E


Publication Contributing Sources